/NKTR
NKTR Stock - Nektar Therapeutics
Healthcare|BiotechnologyNASDAQ
$46.84+6.45%
+$2.84 (+6.45%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.69
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+164.0%upside
Target: $123.66
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NKTR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$46.37 – $47.31
TARGET (TP)$123.67
STOP LOSS$43.09
RISK/REWARD1:20.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.28
52W High$66.92
52W Low$6.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $98.43M | $90.12M | $92.06M | $101.91M | $152.91M |
| Gross Profit | $67.74M | $53.48M | $70.42M | $77.01M | $133.44M |
| Gross Margin | 68.8% | 59.3% | 76.5% | 75.6% | 87.3% |
| Operating Income | $-105,198,000 | $-137,425,000 | $-240,236,000 | $-446,103,000 | $-379,922,000 |
| Net Income | $-118,961,000 | $-276,056,000 | $-368,198,000 | $-523,837,000 | $-444,440,000 |
| Net Margin | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% |
| EPS | $-8.68 | $-21.79 | $-29.51 | $-42.90 | $-37.33 |
Company Overview
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
71%
Hold / Neutral
2
14%
Sell / Underperform
2
14%
Analyst Consensus🟢 Bullish
10 Bullish4 Neutral/Bearish
Price Targets
$26
Average Target
↓ 44.6% Downside
Now
$1
Low
$26
Average
$120
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 26th 2025 | Citigroup | Initiation | Buy | $102 |
| June 24th 2025 | BTIG Research | Reiterated | Buy | $100← $60 |
| June 24th 2025 | H.C. Wainwright | Reiterated | Buy | $120← $6.5 |
| April 11th 2025 | Jefferies | Upgrade | Buy | $2 |
| March 14th 2025 | Oppenheimer | Upgrade | Outperform | $6 |
| January 8th 2025 | B. Riley Securities | Initiation | Buy | $4 |
| December 10th 2024 | H.C. Wainwright | Initiation | Buy | $6.5 |
| November 4th 2024 | Piper Sandler | Initiation | Overweight | $7 |
| September 30th 2024 | BTIG Research | Resumed | Buy | $4 |
| June 28th 2024 | Rodman & Renshaw | Initiation | Buy | $2 |
| November 20th 2023 | JP Morgan | Resumed | Underweight | - |
| November 9th 2023 | TD Cowen | Upgrade | Outperform | - |
| May 10th 2023 | Jefferies | Upgrade | Hold | $1← $1.5 |
| February 24th 2023 | Jefferies | Downgrade | Underperform | $1.5← $3.2 |
| August 8th 2022 | JP Morgan | Downgrade | Underweight | - |
Earnings History & Surprises
NKTRBeat Rate
72%
Last 18 quarters
Avg Surprise
+9.1%
EPS vs Estimate
Beats / Misses
13/5
Last 12 quarters
Latest EPS
$-1.85
Q4 2025
EPS Surprise History
Q1 24
-10.0%
$-0.22vs$-0.20
Q2 24
+14.3%
$-0.18vs$-0.21
Q3 24
-19.0%
$-0.25vs$-0.21
Q4 24
+21.7%
$-0.18vs$-0.23
Q1 25
-15.4%
$-2.25vs$-1.95
Q2 25
-22.2%
$-3.30vs$-2.70
Q3 25
+5.8%
$-2.95vs$-3.13
Q4 25
+35.1%
$-1.85vs$-2.85
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | $-2.69 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-2.85 | $-1.85 | +35.1% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-3.13 | $-2.95 | +5.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-2.70 | $-3.30 | -22.2% | ✗ MISS |
Q1 2025 | Mar 12, 2025 | $-1.95 | $-2.25 | -15.4% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.21 | $-0.25 | -19.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q1 2024 | Mar 4, 2024 | $-0.20 | $-0.22 | -10.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.18 | $-0.19 | -5.6% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.26 | $-0.25 | +3.8% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.45 | $-0.32 | +28.9% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.47 | $-0.24 | +48.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-1.01 | $-0.85 | +15.8% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.72 | $-0.49 | +31.9% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.81 | $-0.79 | +2.5% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.80 | $-0.70 | +12.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.72 | $-0.69 | +4.2% | ✓ BEAT |
Latest News
HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $135
📈 PositiveBenzinga•Dec 16, 2025, 05:52 PM
Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 16, 2025, 01:25 PM
Nektar rises after mid-stage trial data for lead asset in hair loss disorder
📈 PositiveSeeking Alpha•Dec 16, 2025, 01:16 PM
Nektar Reports Phase 2 Results for Hair Loss Treatment, Misses Initial Stat Target
📉 NegativeBenzinga•Dec 16, 2025, 12:33 PM
Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending
📉 NegativeBenzinga•Dec 16, 2025, 12:25 PM
Nektar To Hold Conference Call To Discuss Topline Results From The 36-Week Induction Treatment Period For Its REZOLVE-AA Phase 2b Study Of Rezpegaldesleukin In Alopecia Areata On December 16, 2025 At 8:00 am ET
➖ NeutralBenzinga•Dec 15, 2025, 11:29 PM
Nektar Therapeutics shares are trading higher after Citigroup initiated coverage on the stock with a Buy rating and announced a $102 price target.
📈 PositiveBenzinga•Nov 26, 2025, 07:32 PM•Also:
Citigroup Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $102
📈 PositiveBenzinga•Nov 26, 2025, 07:17 PM•Also:
Nektar Therapeutics Enters Equity Distribution Agreement With Piper Sandler & BTIG; May Sell Shares Worth Up To $110M
➖ NeutralBenzinga•Nov 12, 2025, 10:31 PM
Nektar Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed
➖ NeutralBenzinga•Nov 12, 2025, 09:46 PM
Reported Saturday, Nektar Therapeutics Presents Late-Breaking REZOLVE-AD Data Showing Clinically Meaningful EASI-75 And EASI-90 Improvements At ACAAI 2025
📈 PositiveBenzinga•Nov 10, 2025, 08:46 AM
Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 7, 2025, 12:15 PM
Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 6, 2025, 10:20 PM
Nektar Therapeutics Q3 EPS $(1.87) Beats $(2.69) Estimate, Sales $11.790M Beat $10.048M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:21 PM
Nektar Therapeutics Announced Data From REZOLVE-AD Phase 2b Study For Rezpegaldesleukin Accepted For Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
📈 PositiveBenzinga•Oct 22, 2025, 12:06 PM
Nektar Therapeutics gains amid takeover speculation
📈 PositiveSeeking Alpha•Oct 17, 2025, 06:32 PM
B. Riley Securities Maintains Buy on Nektar Therapeutics, Raises Price Target to $105
📈 PositiveBenzinga•Sep 23, 2025, 06:09 PM
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $100 Price Target
📈 PositiveBenzinga•Sep 19, 2025, 08:22 AM
Nektar Therapeutics shares are trading higher after the company announced new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin. Rezpegaldesleukin achieved statistical significance on the primary endpoint of mean improvement in Eczema Area and Severity Index at week 16 over baseline for all rezpegaldesleukin arms versus placebo.
📈 PositiveBenzinga•Sep 18, 2025, 01:21 PM
Nektar Therapeutics Announces New Data From Ongoing REZOLVE-AD Phase 2b Study Of Rezpegaldesleukin At 2025 EADV Congress
📈 PositiveBenzinga•Sep 18, 2025, 12:47 PM
Frequently Asked Questions about NKTR
What is NKTR's current stock price?
Nektar Therapeutics (NKTR) is currently trading at $46.84 per share. The stock has moved +6.45% today.
What is the analyst price target for NKTR?
The average analyst price target for NKTR is $123.67, based on 1 analyst.
What sector is Nektar Therapeutics in?
Nektar Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NKTR's market cap?
Nektar Therapeutics has a market capitalization of $0.95 billion, making it a small-cap company.
Does NKTR pay dividends?
No, Nektar Therapeutics does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMLX
Amylyx Pharmaceuticals, Inc.
$12.02
Mkt Cap: $1.0B
ATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SANA
Sana Biotechnology, Inc.
$4.36
Mkt Cap: $1.2B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to NKTR for comparison